Degarelix (acetate), CAS 934016-19-0

Formulation: A crystalline solid

Formal Name: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, monoacetate

Purity: ≥98%

Formula Markup: C82H103ClN18O16 • C2H4O2

Formula Weight: 1692,3

Shelf life (days): 1460

CAS Number: 934016-19-0

Notes: Degarelix is a synthetic gonadotropin-releasing hormone receptor (GNRHR) antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor).{39553} It inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines following a 72-hour incubation at a concentration of 10 μM via caspase activation and induction of apoptosis.{39554} In vivo, degarelix (2 mg/kg) decreases plasma testosterone levels in rats to castrate levels for the first 49 days post administration.{39553} It decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats when administered at a dose of 1 mg/kg per month.{39555} Formulations containing degarelix have been used in the treatment of advanced prostate cancer.

• Artikelnummer: CAY24069-5
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 24069-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK